{"id":"W2955205003","doi":"10.1016/s0140-6736(19)30952-3","title":"Risankizumab compared with adalimumab in patients with moderate-to-severe plaque psoriasis (IMMvent): a randomised, double-blind, active-comparator-controlled phase 3 trial","year":2019,"lang":"en","type":"article","venue":"The Lancet","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":298,"is_retracted":false,"has_abstract":false,"ca_institutions":"Probity Medical Research; Queen's University","funders":"AbbVie Deutschland","keywords":"Adalimumab; Medicine; Plaque psoriasis; Psoriasis; Double blind; Internal medicine; Dermatology; Physical therapy; Alternative medicine; Placebo; Disease; Pathology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002215868,0.00271303,0.005052785,0.000526781,0.0006373358,0.002013059,0.001336562,0.00300238,0.009131205],"category_scores_gemma":[0.002167769,0.001150484,0.004285364,0.0004408481,0.001552612,0.001828061,0.0006470011,0.005317403,0.001815496],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0008541882,"about_ca_system_score_gemma":0.0008392588,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001374881,"about_ca_topic_score_gemma":0.002443588,"domain_scores_codex":[0.999194,0.0003634704,0.00005619452,0.0001661402,0.00006672647,0.0001534821],"domain_scores_gemma":[0.999186,0.000283732,0.0001839,0.00006728142,0.0000543731,0.0002247984],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9902479,0.001107958,0.0001732342,0.0007191356,0.001064413,0.0000273726,0.00003203094,0.0001296495,0.0008246094,0.00009506169,0.0006066489,0.00497194],"study_design_scores_gemma":[0.98741,0.01105466,0.0004857104,0.00003300845,0.0003992473,0.00001811631,0.00001350534,0.0001307802,0.00007563012,0.0001170832,0.0002528061,0.000009350342],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9574101,0.02258016,0.001715504,0.002392069,0.003410961,0.004526342,0.002356695,0.0004488666,0.005159183],"genre_scores_gemma":[0.9760894,0.006483818,0.002050006,0.002878815,0.00131422,0.003616723,0.001516424,0.00007255845,0.005978094],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.009131205,"threshold_uncertainty_score":0.0305469,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02777645246813299,"score_gpt":0.2690698673153367,"score_spread":0.2412934148472037,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}